Use of Low Molecular Weight Heparin in Covid-19 patients

A number of organ-specific and systemic phenotypes have been added by the COVID-19 pandemic, others previously identified in viral infections, including severe acute respiratory syndrome (SARS) and others that seem to be unique to SARS-coronavirus (CoV)-2. The Coronavirus disease 2019 (COVID-19) pathogenesis is increasingly being recognized. Along with the mortality benefits of Heparin, a high number of thrombotic episodes are recorded. It is possible to view COVID-19 as a prothrombotic illness. Management recommendations are driven by increasingly evolving information from scientific observations, autopsy-based results, and extrapolations from in vitro and ex vivo experiments and complex modelling; however, several issues remain unanswered and scientific trials that are needed to include proof in most fields have not been conducted. Also, this is supported by several coagulation markers. COVID-19 can be considered as a thrombosis risk factor. Objective: The following review summarizes emerging findings into pathobiology, mechanism(s), diagnosis, administration, scientific foundations, and proposed or continuing COVID-19-associated coagulopathy clinical trials and use of Heparin in COVID-19 patients. Conclusion: Stratifying high-risk thrombosis patients, particularly the elderly, those with comorbidities and high D-Dimer levels is an important step to prevent thromboembolism in COVID-19 patients.

Author(s):

Aishwarya Anand*, Radhika. A. R

Abstract | Full-Text | PDF

Share this